1. Search Result
Search Result
Isoforms Recommended: IL-15
Results for "

IL-15

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

11

Inhibitory Antibodies

1

Natural
Products

32

Recombinant Proteins

1

Isotope-Labeled Compounds

6

Antibodies

1

Click Chemistry

11

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100754
    Ritlecitinib
    Maximum Cited Publications
    8 Publications Verification

    PF-06651600

    JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib
  • HY-113016
    Elaidic acid
    4 Publications Verification

    Apoptosis Wnt ERK Bacterial Interleukin Related Infection Metabolic Disease Cancer
    Elaidic acid is an orally active trans fatty acid. Elaidic acid enhances the stemness of colorectal cancer cells by activating the Wnt/ERK1/2 pathway, thereby promoting cell proliferation, invasion and metastasis, and inhibiting apoptosis. Elaidic acid also inhibits the growth of Lactobacillus and alters the cell surface hydrophobicity of Lactobacillus. Elaidic acid reduces basal 2-deoxyglucose uptake in muscle cells and adipocytes. Elaidic acid can be used in research on colorectal cancer, insulin and other related areas .
    Elaidic acid
  • HY-132580
    Tofersen
    2 Publications Verification

    BIIB067; ISIS-SOD1Rx; ISIS 333611

    SOD Neurological Disease
    Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
    Tofersen
  • HY-P99410

    AMG 714; PRV-015

    Interleukin Related Inflammation/Immunology
    Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
    Ordesekimab
  • HY-132580A
    Tofersen sodium
    2 Publications Verification

    BIIB067 sodium; ISIS-SOD1Rx sodium; ISIS 333611 sodium

    SOD Neurological Disease
    Tofersen (BIIB067) sodium is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen sodium mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen sodium downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen sodium can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
    Tofersen sodium
  • HY-P990223

    Interleukin Related Infection Others Inflammation/Immunology Cancer
    Anti-Mouse IL-15 Antibody (AIO.3) is a rat-derived IgG2a λ type antibody inhibitor, targeting to mouse IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can neutralize IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can be used for the researches of cancer, infection and inflammation, such as hepatitis virus infection and esophagitis .
    Anti-Mouse IL-15 Antibody (AIO.3)
  • HY-Y0493

    HOOBt

    STAT HIV Infection Cancer
    HODHBt (HOOBt) inhibits STAT5-SUMO interaction by blocking SUMOylation of phosphorylated STAT5. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer .
    HODHBt
  • HY-100754C
    Ritlecitinib tosylate
    Maximum Cited Publications
    8 Publications Verification

    PF-06651600 tosylate

    JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib tosylate
  • HY-15898
    Y-320
    5 Publications Verification

    Interleukin Related Apoptosis Inflammation/Immunology Cancer
    Y-320 is a potent, orally active phenylpyrazoleanilide immunomodulator. Y-320 inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 values of 20 to 60 nM. Y-320 enhances TP53, DMD, and COL17A1 PTC readthrough by G418 and increases cellular protein levels and protein synthesis. Y-320 concomitants use of with a low dose of Paclitaxel (HY-B0015) significantly sensitized multidrug resistance (MDR) tumors by inducing G2/M phase arrest and apoptosis. Y-320 can be used for research of rheumatoid arthritis (RA) and cancer .
    Y-320
  • HY-P99661
    Inbakicept
    2 Publications Verification

    Interleukin Related Cancer
    Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
    Inbakicept
  • HY-P99850

    GSK-3511294

    Interleukin Related Inflammation/Immunology
    Depemokimab (GSK-3511294) is a long-acting anti-IL-5 monoclonal antibody. Depemokimab can be used for research of asthma .
    Depemokimab
  • HY-102049

    Interleukin Related Inflammation/Immunology
    IL-15-IN-1 (compound 76) is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM .
    IL-15-IN-1
  • HY-P99759

    IL-15N72D

    Interleukin Related Inflammation/Immunology Cancer
    Nogapendekin alfa (his tag), a soluble protein subunit of a human interleukin (IL)-15 variant, is a superagonist of IL-15. Nogapendekin alfa (his tag) promotes the proliferation and viability of immune cells. Nogapendekin alfa (his tag) combines with Inbakicept (HY-P99661) at a ratio of 2:1, to form N-803 (Nogapendekin alfa inbakicept), an IL-15 cytokine antibody fusion protein. N-803 reduces tumor burden by activation of NK cells and CD8 + T cells .
    Nogapendekin alfa (his tag)
  • HY-P990446

    DISC0280

    Interleukin Related Inflammation/Immunology
    The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed human antibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-IL-15 Antibody (DISC0280)
  • HY-P990808

    Interleukin Related Infection Metabolic Disease Inflammation/Immunology Cancer
    Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) is a rat-derived IgG2b κ type antibody inhibito, targeting to mouse CD122/IL-2Rβ. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can block IL-2 and IL-15. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can deplete natural killer (NK) cells and NKT cells. Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) can be used for the researches of cancer, infection, inflammation, immunology and metabolic disease, such as melanoma, experimental autoimmune encephalomyelitis (EAE) and diabetes .
    Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1)
  • HY-RS06690

    Small Interfering RNA (siRNA) Interleukin Related Others

    IL15 Human Pre-designed siRNA Set A contains three designed siRNAs for IL15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL15 Human Pre-designed siRNA Set A
    IL15 Human Pre-designed siRNA Set A
  • HY-RS06691

    Small Interfering RNA (siRNA) Interleukin Related Others

    Il15 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il15 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il15 Mouse Pre-designed siRNA Set A
    Il15 Mouse Pre-designed siRNA Set A
  • HY-174636

    mRNA Inflammation/Immunology
    Human IL15 mRNA encodes the human interleukin 15 (IL15) protein, a cytokine that regulates T and natural killer cell activation and proliferation. IL15 induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6.
    Human IL15 mRNA
  • HY-153050

    JAK Inflammation/Immunology Cancer
    JAK-IN-24 is a JAK inhibitor, with IC50s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC50 of 86.171 nM . JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    JAK-IN-24
  • HY-RS06692

    Small Interfering RNA (siRNA) Interleukin Related Others

    Il15 Rat Pre-designed siRNA Set A contains three designed siRNAs for Il15 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il15 Rat Pre-designed siRNA Set A
    Il15 Rat Pre-designed siRNA Set A
  • HY-P990719

    XmAb24306

    Interleukin Related Inflammation/Immunology Cancer
    Efbalropendekin Alfa (XmAb24306) is an IL-15/IL-15 receptor alpha complex fused to a heterodimeric Fc domain (IL15/IL15Rα-Fc). Efbalropendekin Alfa increases direct and antibody-dependent cellular cytotoxicity (ADCC)-mediated human natural killer (NK) cell cytotoxicity in vitro .
    Efbalropendekin alfa
  • HY-100754A

    PF-06651600 malonate

    JAK Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib malonate
  • HY-132580S

    BIIB067-d27; ISIS-SOD1Rx-d27; ISIS 333611-d27

    Isotope-Labeled Compounds SOD Neurological Disease
    Tofersen-d27 (BIIB067-d27) is the deuterium labeled Tofersen (HY-132580). Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis.
    Tofersen-d27
  • HY-P991005

    Interleukin Related Inflammation/Immunology
    HY-P991005 is an IL-15RA-targeting Fusion Protein .
    Larnefpendekin alfa
  • HY-RS06693

    Small Interfering RNA (siRNA) Others

    IL15RA Human Pre-designed siRNA Set A contains three designed siRNAs for IL15RA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    IL15RA Human Pre-designed siRNA Set A
    IL15RA Human Pre-designed siRNA Set A
  • HY-RS26277

    Small Interfering RNA (siRNA) Others

    Il15ra Rat Pre-designed siRNA Set A contains three designed siRNAs for Il15ra gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il15ra Rat Pre-designed siRNA Set A
    Il15ra Rat Pre-designed siRNA Set A
  • HY-RS19780

    Small Interfering RNA (siRNA) Others

    Il15ra Mouse Pre-designed siRNA Set A contains three designed siRNAs for Il15ra gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Il15ra Mouse Pre-designed siRNA Set A
    Il15ra Mouse Pre-designed siRNA Set A
  • HY-P992375

    Interleukin Related Inflammation/Immunology
    HuMax-IL15 is a human IgG1 monoclonal antibody against IL-15. HuMax-IL15 is applicable to the research of rheumatoid arthritis. The recommended isotype control is human IgG1 kappa (HY-P99001) .
    HuMax-IL15
  • HY-102049R

    Reference Standards Interleukin Related Inflammation/Immunology
    IL-15-IN-1 (Standard) is the analytical standard of IL-15-IN-1 (HY-102049). This product is intended for research and analytical applications. IL-15-IN-1 (compound 76) is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM .
    IL-15-IN-1 (Standard)
  • HY-174635

    mRNA Inflammation/Immunology
    Human IL15RA mRNA encodes the human interleukin 15 receptor subunit alpha (IL15RA) protein, a cytokine receptor that specifically binds interleukin 15 (IL15) with high affinity. IL15RA is reported to enhance cell proliferation and expression of apoptosis inhibitor BCL2L1/BCL2-XL and BCL2.
    Human IL15RA mRNA
  • HY-P992030

    Transmembrane Glycoprotein Inflammation/Immunology
    FB102 is an anti-human CD122 (IL-2Rβ) monoclonal antibody with selective activity. FB102 blocks the proliferation and activation of pathogenic NK cells and specific T cell subsets induced by IL-2 and IL-15, without affecting the proliferation of regulatory T cells. FB102 inhibits IL-2/IL-15-induced activation of CD4+ and CD8+ T cells in in vitro disease models. FB102 is applicable to research related to celiac disease .
    FB102
  • HY-100754R

    PF-06651600 (Standard)

    JAK Reference Standards Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (Standard) is the analytical standard of Ritlecitinib (HY-100754). This product is intended for research and analytical applications. Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib (Standard)
  • HY-100754CR

    PF-06651600 tosylate (Standard)

    JAK Reference Standards Interleukin Related STAT Inflammation/Immunology
    Ritlecitinib (tosylate) (Standard) is the analytical standard of Ritlecitinib (tosylate) (HY-100754C). This product is intended for research and analytical applications. Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .
    Ritlecitinib tosylate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: